
The retrospective study assessed topical 5% imiquimod for oral leukoplakia, finding that 68.4% of lesions had a ≥50% size reduction. Common adverse events were local site reactions and fatigue. Prospective studies are needed to confirm effectiveness.
Like
Save
Share